drugset
drugset / Trial / NCT05319275

Study of Acetyllevocarnitine Hydrochloride Tablets in Chinese Patients With Paresthesias Caused by DPN

NCT05319275 ↗

Phase 3 Completed 516 enrolled Haisco Pharmaceutical Group Co., Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to assess the efficacy of Acetyllevocarnitine Hydrochloride Tablets compared with placebo after 24 weeks, in chinese patients with paresthesia caused by Diabetic Peripheral Neuropathy (DPN).

Timeline

Start
2020-07-23
Primary completion
2021-12-07
Completion
2022-01-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Acetyllevocarnitine Unknown 500 mg —

Indications

diabetic polyneuropathy